Reversible Posterior Leukoencephalopathy Syndrome in a Patient Treated With Ustekinumab: Case Report and Review of the Literature | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.108.182. Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
Observation
Oct 2011

Reversible Posterior Leukoencephalopathy Syndrome in a Patient Treated With Ustekinumab: Case Report and Review of the Literature

Author Affiliations

Author Affiliations: International Dermatology Research, Inc (Dr Gratton), and H ôpital de Verdun, Universit é de Montr éal (Drs Germain and Saltiel), Montreal, Canada; Centocor Research & Development, Inc (Dr Szapary), and Johnson & Johnson Pharmaceutical Research & Development, LLC (Dr Goyal), Malvern, Pennsylvania; and Centocor Ortho Biotech Services, LLC, Horsham, Pennsylvania (Dr Fakharzadeh).

Arch Dermatol. 2011;147(10):1197-1202. doi:10.1001/archdermatol.2011.161
Abstract

Background Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare, generally reversible neurologic syndrome that is diagnosed based on characteristic clinical and radiologic findings.

Observations We describe the first case of RPLS in a 65-year-old woman who underwent ustekinumab therapy for psoriasis. Approximately 2 ½ years after the patient began ustekinumab therapy, she experienced an acute onset of confusion, headache, nausea, vomiting, and seizures. Computed tomographic scans and magnetic resonance images of her head revealed characteristic findings, including white matter abnormalities consistent with edema in the absence of infarction. There was no evidence of vasospasm, thrombosis, or infection. Cerebrospinal fluid tests were negative for the JC virus. The patient improved clinically and was discharged 6 days after she presented to the emergency department. She made a full neurologic recovery, with a reversal of the radiologic findings.

Conclusions Reversible posterior leukoencephalopathy syndrome is an increasingly recognized neurologic disorder that has been reported with the use of systemic and biologic agents to treat moderate to severe psoriasis. Although the relationship between RPLS and ustekinumab therapy remains unclear, this case emphasizes the need for dermatologists to recognize the syndrome's signs and symptoms and to refer patients promptly for evaluation and appropriate treatment if the clinical features of RPLS are suspected.

×